Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Biol Reprod ; 108(3): 359-362, 2023 03 13.
Artículo en Inglés | MEDLINE | ID: mdl-36611017

RESUMEN

Forkhead box protein A2 (FOXA2) is a pioneer transcription factor important for epithelial budding and morphogenesis in different organs. It has been used as a specific marker for uterine glandular epithelial cells (GE). FOXA2 has close interactions with estrogen receptor α (ERα). ERα binding to Foxa2 gene in the uterus indicates its regulation of Foxa2. The intimate interactions between ERα and FOXA2 and their essential roles in early pregnancy led us to investigate the expression of FOXA2 in the female reproductive tract of pre-implantation epiERα-/- (Esr1fl/flWnt7aCre/+) mice, in which ERα is conditionally deleted in the epithelium of reproductive tract. In the oviduct, FOXA2 is detected in the ciliated epithelial cells of ampulla but absent in the isthmus of day 3.5 post-coitum (D3.5) Esr1fl/fl control and epiERα-/- mice. In the uterus, FOXA2 expression in the GE appears to be comparable between Esr1fl/fl and epiERα-/- mice. However, FOXA2 is upregulated in the D0.5 and D3.5 but not PND25-28 epiERα-/- uterine luminal epithelial cells (LE). In the vagina, FOXA2 expression is low in the basal layer and increases toward the superficial layer of the D3.5 Esr1fl/fl vaginal epithelium, but FOXA2 is detected in the basal, intermediate, and superficial layers, with the strongest FOXA2 expression in the intermediate layers of the D3.5 epiERα-/- vaginal epithelium. This study demonstrates that loss of ERα in LE and vaginal basal layer upregulates FOXA2 expression in these epithelial cells during early pregnancy. The mechanisms for epithelial cell-type specific regulation of FOXA2 by ERα remain to be elucidated.


Asunto(s)
Receptor alfa de Estrógeno , Útero , Animales , Femenino , Ratones , Embarazo , Epitelio/metabolismo , Receptor alfa de Estrógeno/genética , Receptor alfa de Estrógeno/metabolismo , Factor Nuclear 3-beta del Hepatocito/genética , Factor Nuclear 3-beta del Hepatocito/metabolismo , Regulación hacia Arriba , Útero/metabolismo , Vagina/metabolismo
2.
Biol Reprod ; 105(6): 1521-1532, 2021 12 20.
Artículo en Inglés | MEDLINE | ID: mdl-34554181

RESUMEN

Certain chemotherapeutic drugs are toxic to ovarian follicles. The corpus luteum (CL) is normally developed from an ovulated follicle for producing progesterone (P4) to support early pregnancy. To fill in the knowledge gap about effects of chemotherapy on the CL, we tested the hypothesis that chemotherapy may target endothelial cells and/or luteal cells in the CL to impair CL function in P4 steroidogenesis using doxorubicin (DOX) as a representative chemotherapeutic drug in mice. In both mixed background mice and C57BL/6 mice, a single intraperitoneal injection of DOX (10 mg/kg) on 0.5-day postcoitum (D0.5, postovulation) led to ~58% D3.5 mice with serum P4 levels lower than the serum P4 range in the phosphate buffer saline-treated control mice. Further studies in the C57BL/6 ovaries revealed that CLs from DOX-treated mice with low P4 levels had less defined luteal cords and disrupted collagen IV expression pattern, indicating disrupted capillary, accompanied with less differentiated luteal cells that had smaller cytoplasm and reduced StAR expression. DOX-treated ovaries had increased granulosa cell death in the growing follicles, reduced proliferating cell nuclear antigen-positive endothelial cells in the CLs, enlarged lipid droplets, and disrupted F-actin in the luteal cells. These novel data suggest that the proliferating endothelial cells in the developing CL may be the primary target of DOX to impair the vascular support for luteal cell differentiation and subsequently P4 steroidogenesis. This study fills in the knowledge gap about the toxic effects of chemotherapy on the CL and provides critical information for risk assessment of chemotherapy in premenopausal patients.


Asunto(s)
Antibióticos Antineoplásicos/toxicidad , Cuerpo Lúteo/efectos de los fármacos , Doxorrubicina/toxicidad , Animales , Femenino , Inyecciones Intraperitoneales , Ratones , Ratones Endogámicos C57BL , Embarazo , Preñez
3.
Biol Reprod ; 100(4): 869-871, 2019 04 01.
Artículo en Inglés | MEDLINE | ID: mdl-30561525

RESUMEN

Chemotherapy can potentially impair fertility in premenopausal cancer patients. Female fertility preservation has been mainly focused on the ovarian aspects and benefited greatly from assisted reproductive technologies, such as in vitro fertilization (IVF). The rate-limiting step for the success of IVF is embryo implantation in the uterus. Doxorubicin (DOX) is a widely used chemotherapeutic agent with ovarian toxicity. It remains unknown if the uterus is a direct target of DOX. To circumvent the indirect uterine effect from ovarian toxicity of DOX and to investigate potential long-term impact of DOX on the uterus, young adult ovariectomized CD-1 mice were given an intraperitoneal injection once with PBS or DOX (10 mg/kg, a human relevant chemotherapeutic dose), and 30 days later, each set of mice was randomly assigned into three groups and subcutaneously injected with oil, 17ß-estradiol (E2, for 6 h), and progesterone (P4, for 54 h), respectively. Uterine transcriptomic profiles were determined using RNA-seq. Principal component analysis of the uterine transcriptomes revealed four clusters from the six treatment groups: PBS-oil & DOX-oil, PBS-P4 & DOX-P4, PBS-E2, and DOX-E2, indicating that DOX treatment did not affect the overall uterine transcriptomic profiles in the oil and P4-treated mice but altered uterine responses to E2 treatment. DAVID analysis indicated that the top-affected gene cluster was "Glycoprotein". These data demonstrate that DOX can directly target the uterus and has a long-term impact on uterine responses to E2.


Asunto(s)
Doxorrubicina/farmacología , Estradiol/farmacología , Expresión Génica/efectos de los fármacos , Transcriptoma/efectos de los fármacos , Útero/efectos de los fármacos , Animales , Femenino , Perfilación de la Expresión Génica , Ratones , Análisis por Micromatrices , Ovariectomía , Maduración Sexual/efectos de los fármacos , Maduración Sexual/fisiología , Útero/metabolismo
5.
Reprod Toxicol ; 85: 42-50, 2019 04.
Artículo en Inglés | MEDLINE | ID: mdl-30772436

RESUMEN

Zearalenone (ZEA) is a common food contaminant (ppb-ppm) derived from Fusarium fungi. With its estrogenicity and potential chronic exposure, ZEA poses a risk to pregnancy. Our previous studies implied post-implantational lethality by ZEA. Since a functional placenta is essential for fetal development and survival, it was hypothesized that ZEA may have adverse effects on placental development leading to post-implantational lethality. Exposure of young mice to 0, 0.8, 4, 10, and 40 ppm ZEA diets from gestation day 5.5 (D5.5) to D13.5 led to increased resorption of implantation sites, increased placental hemorrhage, decreased placental and fetal weights, proportionally reduced placental layers, and disorganized placental labyrinth vascular spaces in the 40 ppm ZEA group, as well as lipid accumulation in the labyrinth layer of all four ZEA treatment groups examined on D13.5. These data demonstrate adverse effects of ZEA on placental development.


Asunto(s)
Exposición Dietética/efectos adversos , Placentación/efectos de los fármacos , Zearalenona/toxicidad , Animales , Implantación del Embrión , Femenino , Queratina-19/metabolismo , Laminina/metabolismo , Intercambio Materno-Fetal , Ratones Endogámicos C57BL , Placenta/efectos de los fármacos , Placenta/metabolismo , Placenta/patología , Embarazo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA